Suppr超能文献

使用非自体微囊化细胞将重组基因产物递送至犬类。

Delivery of recombinant gene product to canines with nonautologous microencapsulated cells.

作者信息

Peirone M A, Delaney K, Kwiecin J, Fletch A, Chang P L

机构信息

Department of Biology, McMaster University, Hamilton, Ontario, Canada.

出版信息

Hum Gene Ther. 1998 Jan 20;9(2):195-206. doi: 10.1089/hum.1998.9.2-195.

Abstract

An alternative and potentially cost-effective approach to somatic gene therapy is to engineer a universal cell line secreting the desired product suitable for implantation into different patients without immune rejection. Encapsulating these cells in immunoprotective alginate microcapsules showed that this approach was effective in treating murine models of human diseases. We now report that this approach is also effective in delivering recombinant gene products to large animals. Canine MDCK cells encapsulated in alginate microcapsules were able to deliver recombinant human growth hormone to nonautologous dogs in vivo. However, the same microcapsules capable of prolonged delivery in mice soon disappeared after implantation in dogs. In contrast, when these microcapsules were modified by using a higher concentration of alginate cross-linked with barium instead of calcium, and by fabricating the alginate as a gelled bead without solubilizing the core, more prolonged and higher levels of recombinant product were obtained. Laminating the surface of the beads with poly-L-lysine and alginate provided an even more mechanically stable device that lasted for >2 months instead of <14 days in vivo and delivered >20 ng of human growth hormone/ml of plasma within the first week. The apparent disappearance of the growth hormone from the circulation after day 14 was due to rapid clearance by anti-human growth hormone antibodies and not due to loss of cell viability. However, all microcapsules provoked an inflammatory reaction, causing mild omentitis, and eventually disappeared from the intraperitoneal cavity. In conclusion, systemic delivery of recombinant gene products with nonautologous cells protected in alginate microcapsules has been shown to be feasible in canine recipients. While improved level and duration of delivery have been achieved by increasing the mechanical stability of the microcapsules, further improvements in biocompatibility and stability will be required for human application.

摘要

一种替代的且可能具有成本效益的体细胞基因治疗方法是构建一种通用细胞系,该细胞系分泌适合植入不同患者体内且不会引发免疫排斥的所需产物。将这些细胞封装在免疫保护藻酸盐微胶囊中表明,这种方法在治疗人类疾病的小鼠模型中是有效的。我们现在报告,这种方法在向大型动物递送重组基因产物方面也是有效的。封装在藻酸盐微胶囊中的犬源MDCK细胞能够在体内向非自体犬递送重组人生长激素。然而,同样的微胶囊在小鼠体内能够实现长期递送,但在植入犬体内后很快就消失了。相比之下,当使用更高浓度的藻酸盐与钡而非钙交联,并将藻酸盐制成凝胶珠而不溶解核心来修饰这些微胶囊时,可获得更长时间且更高水平的重组产物。用聚-L-赖氨酸和藻酸盐层压珠子表面提供了一种机械稳定性更高的装置,其在体内持续时间超过2个月而非不到14天,并且在第一周内每毫升血浆递送超过20纳克的人生长激素。第14天后循环中生长激素明显消失是由于抗人生长激素抗体的快速清除,而非细胞活力丧失。然而,所有微胶囊都引发了炎症反应,导致轻度大网膜炎,最终从腹腔中消失。总之,在犬类受体中,用封装在藻酸盐微胶囊中的非自体细胞进行重组基因产物的全身递送已被证明是可行的。虽然通过提高微胶囊的机械稳定性实现了递送水平和持续时间的改善,但在人类应用中还需要进一步提高生物相容性和稳定性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验